Literature DB >> 21785541

Treatment options for obesity and potential therapies on the horizon.

Carol A Motycka, Erin St Onge, Shannon A Miller.   

Abstract

Entities:  

Year:  2011        PMID： 21785541      PMCID： PMC3138370     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  41 in total

1.  Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials.

Authors:  C K Haddock; W S C Poston; P L Dill; J P Foreyt; M Ericsson
Journal:  Int J Obes Relat Metab Disord       Date:  2002-02

2.  A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.

Authors:  N L Cluny; V K Vemuri; A P Chambers; C L Limebeer; H Bedard; J T Wood; B Lutz; A Zimmer; L A Parker; A Makriyannis; K A Sharkey
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial.

Authors:  S B Heymsfield; A S Greenberg; K Fujioka; R M Dixon; R Kushner; T Hunt; J A Lubina; J Patane; B Self; P Hunt; M McCamish
Journal:  JAMA       Date:  1999-10-27       Impact factor: 56.272

Review 4.  The endocannabinoid system and the treatment of obesity.

Authors:  Uberto Pagotto; Valentina Vicennati; Renato Pasquali
Journal:  Ann Med       Date:  2005       Impact factor: 4.709

5.  In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.

Authors:  John R Hadcock; David A Griffith; Phillip A Iredale; Phillip A Carpino; Robert L Dow; Shawn C Black; Rebecca O'Connor; Denise Gautreau; Jeffrey S Lizano; Karen Ward; Diane M Hargrove; Dawn Kelly-Sullivan; Dennis O Scott
Journal:  Biochem Biophys Res Commun       Date:  2010-03-06       Impact factor: 3.575

6.  Pharmacotherapy for obesity.

Authors:  Mingfang Li; Bernard M Y Cheung
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

7.  Rational design of a combination medication for the treatment of obesity.

Authors:  Frank L Greenway; M J Whitehouse; Maria Guttadauria; James W Anderson; Richard L Atkinson; Ken Fujioka; Kishore M Gadde; Alok K Gupta; Patrick O'Neil; Donald Schumacher; Diane Smith; Eduardo Dunayevich; Gary D Tollefson; Eckard Weber; Michael A Cowley
Journal:  Obesity (Silver Spring)       Date:  2008-11-06       Impact factor: 5.002

Review 8.  The efficacy and safety of sibutramine for weight loss: a systematic review.

Authors:  David E Arterburn; Paul K Crane; David L Veenstra
Journal:  Arch Intern Med       Date:  2004-05-10

9.  Efficacy of exogenous recombinant murine leptin in lean and obese 10- to 12-mo-old female CD-1 mice.

Authors:  M A Pelleymounter; M J Cullen; D Healy; R Hecht; D Winters; M McCaleb
Journal:  Am J Physiol       Date:  1998-10

10.  Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).

Authors:  Peter Kopelman; Gerrit de H Groot; Aila Rissanen; Stephan Rossner; Soren Toubro; Richard Palmer; Rob Hallam; Andrew Bryson; Roger I Hickling
Journal:  Obesity (Silver Spring)       Date:  2009-05-21       Impact factor: 5.002
View more
  1 in total

1.  Forearm blood flow response to acute exercise in obese and non-obese males.

Authors:  R Lee Franco; B A Fallow; C J Huang; E O Acevedo; J A Arrowood; R K Evans
Journal:  Eur J Appl Physiol       Date:  2013-04-05       Impact factor: 3.078
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.